Industry Research Report: The Future Of Clinical Trials

All new medicines—from painkillers and antibiotics to cancer treatments, vaccines, and Alzheimer’s drugs—have one thing in common: they must go through rigorous clinical trials before they are approved and made available to the public. This would not be possible without patients, however. Patients are a crucial part of every clinical trial and their willingness to take part—and to follow through to the end—is paramount.

Over the last few decades, the healthcare industry has made good progress in addressing patient needs, making clinical trials more efficient, and putting patients at the center of clinical research. But the sector and its regulators are, understandably, conservative and change has tended to be tentative and cautious since people’s lives are involved.

This report looks at how clinical trials have changed and are continuing to evolve. It details insights from 400 clinical trial executives across the United Kingdom, France, Germany, and Switzerland who took part in a survey conducted by Vanson Bourne and sponsored by Medidata.

Key takeaways include:

• Clinical trial processes will never be the same.
• Demand for decentralized solutions continues to rise.
• Clinical trials will become more reliant on technological solutions. 
• Patient centricity continues to be a key focus.

Discover what else experts had to say in this industry research report.